Payment overview · 2025
General Payments
$293.95
16 reported records · 10 companies
Healthcare provider profile · identity verified
Scott Michael Ehresman, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOLDREGE, NE · NPI 1972548477
Verified facts
What the public records show
CMS Open Payments records show Scott Michael Ehresman, M.D. received $293.95 in general payments during 2025 across 16 reported records.
Astellas Pharma US Inc accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Myrbetriq by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $68.31 | 23.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.06 | 17.0% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $45.70 | 15.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.17 | 12.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.40 | 6.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.27 | 5.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.74 | 5.0% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.71 | 5.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.82 | 4.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.77 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $293.95 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $68.31 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.06 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.06 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $45.70 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| KOSELUGO Normalized: koselugo |
Drug | Alexion Pharmaceuticals, Inc. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
199 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
180 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 714 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 705 | 100 |
| Potassium Chloride | Potassium Chloride | 587 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 513 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 513 | 81 |
| Sertraline Hcl | Sertraline Hcl | 390 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 364 | 66 |
| Gabapentin | Gabapentin | 341 | 47 |
| Lisinopril | Lisinopril | 328 | 49 |
| Furosemide | Furosemide | 319 | 48 |
| Montelukast Sodium | Montelukast Sodium | 318 | 55 |
| Metformin Hcl Er | Metformin Hcl | 304 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 301 | 46 |
| Omeprazole | Omeprazole | 287 | 43 |
| Fenofibrate | Fenofibrate | 268 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 42 |
| Meloxicam | Meloxicam | 252 | 48 |
| Losartan Potassium | Losartan Potassium | 245 | 41 |
| Trazodone Hcl | Trazodone Hcl | 245 | 39 |
| Tramadol Hcl | Tramadol Hcl | 236 | 52 |
| Carvedilol | Carvedilol | 209 | 26 |
| Metformin Hcl | Metformin Hcl | 209 | 26 |
| Myrbetriq | Mirabegron | 199 | 16 |
| Allopurinol | Allopurinol | 194 | 28 |
| Eliquis | Apixaban | 180 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 168 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 158 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 25 |
| Xarelto | Rivaroxaban | 139 | 18 |
| Donepezil Hcl | Donepezil Hcl | 135 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 36 |
| Warfarin Sodium | Warfarin Sodium | 132 | 18 |
| Valsartan | Valsartan | 130 | 21 |
| Buspirone Hcl | Buspirone Hcl | 123 | 15 |
| Bupropion Xl | Bupropion Hcl | 122 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 18 |
| Ezetimibe | Ezetimibe | 115 | 19 |
| Alendronate Sodium | Alendronate Sodium | 111 | 14 |
| Jardiance | Empagliflozin | 101 | 12 |
| Simvastatin | Simvastatin | 101 | 21 |
| Mirtazapine | Mirtazapine | 97 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 97 | 16 |
| Farxiga | Dapagliflozin Propanediol | 95 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 94 | suppressed |
| Topiramate | Topiramate | 94 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 12 |
| Synthroid | Levothyroxine Sodium | 91 | 12 |
| Pregabalin | Pregabalin | 85 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 85 | 22 |
| Famotidine | Famotidine | 83 | 12 |
| Januvia | Sitagliptin Phosphate | 77 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 77 | suppressed |
| Alprazolam | Alprazolam | 76 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 74 | suppressed |
| Spironolactone | Spironolactone | 73 | 14 |
| Baclofen | Baclofen | 71 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 18 |
| Memantine Hcl | Memantine Hcl | 71 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 71 | suppressed |
| Prednisone | Prednisone | 69 | 29 |
| Cefdinir | Cefdinir | 68 | 62 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 11 |
| Glipizide Er | Glipizide | 65 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | suppressed |
| Nabumetone | Nabumetone | 61 | 12 |
| Ozempic | Semaglutide | 60 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 57 | suppressed |
| Azithromycin | Azithromycin | 56 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | suppressed |
| Nystatin | Nystatin | 53 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 31 |
| Gemfibrozil | Gemfibrozil | 46 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Atenolol | Atenolol | 44 | suppressed |
| Celecoxib | Celecoxib | 44 | 18 |
| Levofloxacin | Levofloxacin | 42 | 35 |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Dutasteride | Dutasteride | 40 | suppressed |
| Lorazepam | Lorazepam | 40 | 18 |
| Finasteride | Finasteride | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 11 |
| Risperidone | Risperidone | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Methotrexate | Methotrexate Sodium | 38 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 30 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 28 |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 30 | 29 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 11 |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Febuxostat | Febuxostat | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 16 |
| Digoxin | Digoxin | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 22 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | 18 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Clozapine | Clozapine | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Aprepitant | Aprepitant | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $293.95 · 16 records | Astellas Pharma US Inc | ABRYSVO, CAPLYTA, COMIRNATY, EVENITY, FREESTYLE LIBRE 3, KOSELUGO, LEQVIO, Ozempic, PREVNAR 20, Rybelsus, Veozah, XIFAXAN, ZENPEP | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error